The European Association of Nuclear Medicine
Bajc M, et al. Eur J Nucl Med Mol Imaging 2019; [Epub ahead of print]
Bajc M, et al. Eur J Nucl Med Mol Imaging 2009; 36: 1356-1370
Bajc M, et al. Eur J Nucl Med Mol Imaging 2009; 36: 1528-1538
The Canadian Association of Nuclear Medicine
Technegas™ Functional Lung Imaging
Ventilation SPECT/CT using Technegas™ to quantify pulmonary function
V/Q SPECT using Technegas™ to detect pulmonary embolism
Beyond PE clinical uses - results from clinical studies
Airflow limitation assessment in chronic airway diseases
Images were kindly provided by the Hunter New England Imaging (HNEI) at John Hunter Hospital and clinical data by the Hunter Medical Research Institute (HMRI)
Monitoring treatment response in asthmatic patients
Images and clinical data were kindly provided by the Woolcock Institute of Medical Research
Lung function evaluation before lung volume reduction surgery
Images were kindly provided by Macquarie Medical Imaging (MMI) and clinical data by Macquarie Respiratory & Sleep department at Macquarie University
Latest Clinical References
"V/Q SPECT, using Technegas as the ventilation imaging agent, could diagnose and grade severity of COPD and also estimate preserved lung function in 94 patients. Moreover, V/Q SPECT appears to be a unique tool to reveal the heterogeneity of COPD caused by pulmonary comorbidities such as pulmonary embolism, left heart failure, lung tumor and pneumonia."
"An advantage of using Technegas as the ventilation agent and radiolabelled macro-aggregated albumin microspheres as the perfusion agent is that the deposition pattern is fixed upon administration and thus different patient postures can be studied and the effect of gravity and position determined, even though the scans must be acquired with the subject supine using conventional gamma camera SPECT/CT systems"
"However, the standard technique for V/Q SPECT in the US involves the use of Xenon radiotracer rather than Technegas rendering direct comparison of equivocal rates less useful."
"The optimal tracer for ventilation studies is Technegas, an ultra fine dispersion of 99mTc-labeled carbon. [...] Its main advantage is greater percentage deposition in the alveolar spaces and less undesirable adherence to the central airways, compared with droplet radioaerosols."
"Technegas is in widespread use in Australia and offers a number of clear advantages in the COVID19 patient. The ventilation procedure is faster, reducing time and improving compliance which in turn decreases the risk of room and staff contamination. The apparatus is single use without recirculation and so poses no risk between patients."
"The best option for ventilation evaluation is aerosolized ultraﬁne 99mTc-labeled impregnated carbon particles (Technegas, Cyclopharm, Australia)."
"Technegas is in widespread use in Australia and offers a number of clear advantages over aerosols in the COVID19 patient. Technegas reduces the time for performing the ventilation and improves compliance which decreases the risk of room and staff contamination. The patient administration sets are single use, selfcontained and without recirculation, eliminating risk between patients."
"Ventilation SPECT imaging with Technegas was used as an estimation of regional ventilation [in asthma patients]."